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ABSTRACT:
The clinical pharmacokinetic behavior of paclitaxel (Taxol) is dis-
tinctly nonlinear, with disproportional increases in systemic expo-
sure with an increase in dose. We have recently shown that Cre-
mophor EL, the formulation vehicle used for i.v. administration of
paclitaxel, alters drug distribution as a result of micellar entrap-
ment of paclitaxel, and we speculated that the free drug fraction
(fu) is dependent on dose and time-varying concentrations of Cre-
mophor EL in the central plasma compartment. To test this hy-
pothesis, a reproducible equilibrium dialysis method has been de-
veloped for the measurement of paclitaxel fu in plasma.
Equilibrium dialysis was performed at 37°C in a humidified atmo-
sphere of 5% CO2 using 2.0-ml polypropylene test tubes. Experi-
ments were carried out with 260-ml aliquots of plasma containing
a tracer amount of [G-3H]paclitaxel with high-specific activity
against an equal volume of 0.01 M phosphate buffer (pH 7.4). Drug
concentrations were measured by both reversed-phase HPLC and
liquid scintillation counting. Using this method, fu has been mea-
sured in three patients receiving three consecutive 3-weekly
courses of paclitaxel at dose levels of 135, 175, and 225 mg/m2 and
found to range between 0.036 and 0.079. The method was also
used to define concentration-time profiles of unbound drug, esti-
mated from the product of the total plasma concentration and fu.
Paclitaxel (Taxol; Fig. 1) is a naturally occurring taxane diterpenoid
first extracted from the bark of the Western yew tree, Taxus brevifolia
(Wani et al., 1971). The compound is a potent inhibitor of cell
replication in malignant cells, a property attributed to its ability to
stabilize the microtubule cytoskeleton and to block the transit of
cycling cells from the G2-phase to the M-phase (Verweij et al., 1994;
Sparreboom et al., 1998c). The clinical pharmacokinetics of paclitaxel
(administered as a 3-h i.v. infusion) have been well documented, and
revealed a striking nonlinear disposition profile in plasma with dis-
proportional increases in systemic exposure resulting from a given
increase in dose (Schiller et al., 1994; Sonnichsen et al., 1994; Gianni
et al., 1995; Bhalla et al., 1999; Karlsson et al., 1999).
It has recently been shown that Cremophor EL (CrEL1), the vehicle
used for i.v. drug administration, profoundly influences the cellular
distribution of paclitaxel in human blood (Sparreboom et al., 1999a).
Cellular kinetic experiments indicated that erythrocyte uptake of
paclitaxel was significantly reduced by polyoxyethyleneglycerol tri-
ricinoleate (Fig. 1), the major compound present in CrEL, as a result
of binding to CrEL micelles which, in turn, can reduce the free drug
fraction (fu) available for cellular partitioning (Sparreboom et al.,
1999a). Furthermore, we found that the altered blood distribution is
highly dependent on dose and time-varying concentrations of CrEL in
the central blood compartment during paclitaxel administration (Spar-
reboom et al., 1999b). This latter aspect of a concentration-dependent
binding of paclitaxel to CrEL micelles occurring after therapeutic
doses suggests that the total plasma concentration (Cp), which is
routinely measured, is not reflective of the unbound drug concentra-
tion (Cu). The rationale for monitoring Cu is founded on the basic
pharmacologic tenet that drug bound to protein, or other (macro)mol-
ecules, is unable to cross cell membranes and interact with the active
site. Although this relationship is intuitive, little has been published on
this topic regarding anticancer drugs, with the notable exception of
etoposide (Stewart et al., 1991). Knowledge of the extent of binding
of paclitaxel is of crucial importance for understanding the clinical
pharmacologic behavior of this drug, and could have significant
clinical relevance in view of the fact that relationships between drug
exposure and effect (i.e., toxicity and efficacy) are still poorly defined.
To address these issues, we set out to define a reliable equilibrium
dialysis method and demonstrate its application to binding measure-
ments of paclitaxel in plasma samples of cancer patients receiving
multiple courses of the drug administered by a 3-h i.v. infusion.
Materials and Methods
Chemicals. Paclitaxel powder (batch 484034; purity 98.3% by reversed
phase HPLC) was obtained from Bristol-Myers Squibb (Woerden, The Neth-
erlands). [G-3H]Paclitaxel (batch 227-163-0024; radiochemical purity 99.7%),
with a specific activity of 2.4 Ci/mmol was obtained from Moravek (Brea,
CA). The majority of the tritium label is in the m- and p-positions of the
aromatic rings, with minor amounts in the 10-, 39-, and 2-positions of the
taxane ring system. Ethanol absolute was purchased from Merck (Darmstadt,
Germany), and phosphate-buffered saline from Oxoid (Unipath LTD, Basing-
stoke, Hampshire, UK). The CrEL reference material was obtained from Sigma
Chemicals Co. (St. Louis, MO). Emulsifier-safe scintillation cocktail was
purchased from Packard Instruments Co. (Groningen, The Netherlands).
Equilibrium Dialysis. Paclitaxel fu was measured by equilibrium dialysis
at 37°C in a humidified atmosphere of 5% CO2 using test vials made from
2.0-ml polypropylene Safe-Lock vials (Eppendorf, Hamburg, Germany), car-
rying a 260-ml inside recess in the lids (Reinard and Jacobsen, 1989). Before
incubation, 2 ml of a [G-3H]paclitaxel solution (500-fold diluted in ethanol)
was added to 300 ml of plasma, followed by mixing for 10 s. Dialysis was
1 Abbreviations used are: CrEL, Cremophor EL; fu, fraction unbound; Cp, total
plasma concentration; Cu, unbound concentration; AUC, area under the concen-
tration versus time curve; CL, clearance.
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carried out with 260 ml of this sample against an equal volume of phosphate-
buffered saline (pH 7.4) for 24 h in a moist chamber, which was shown
previously to be sufficiently long to attain equilibrium (Kumar et al., 1993;
Sparreboom et al., 1999a). Spectra/Por 3 dialysis tubing with a 12,500 molec-
ular weight cut-off (Spectrum Medical, Kitchener, Canada) was soaked in
phosphate-buffered saline (pH 7.4) before use. After establishment of the
equilibrium, 150 ml of the buffer solution, containing only unbound paclitaxel,
and 150 ml of the plasma fraction, containing both bound and unbound drug,
were transferred to separate 2-ml vials (Eppendorf) and 1.9 ml of Emulsifier-
Safe scintillation cocktail were added. After manual mixing for 30 s, the
3H-labeled paclitaxel was quantified by liquid scintillation counting using a
Wallac 1409 liquid scintillation counter (Turku, Finland). All samples were
counted until a preset time of 20 min was reached. The ratio of drug concen-
trations measured in the buffer and plasma after dialysis was taken as an
estimate of paclitaxel fu. Because the volume shift during dialysis was negli-
gible (,10%), the results were used directly without applying a correction
factor.
Pharmacokinetic Studies. The three patients studied were a 64-year-old
female with non-small cell lung cancer, a 62-year-old male with bladder
cancer, and a 51-year-old female with a malignant solid tumor of unknown
primary origin for whom paclitaxel as monotherapy was a viable therapeutic
option (Table 1). Before treatment, the patients had a World Health Organi-
zation performance status of ,2, did not receive previous anticancer treatment
with taxanes, and had adequate bone marrow function (white blood cell count,
.3.0 3 109/liter; platelet count, .100 3 109/liter), renal function (serum
creatinine, #140 mM and creatinine clearance .60 ml/min), and hepatic
function (serum bilirubin, alkaline phosphatase, aspartate aminotransferase,
and alanine aminotransferase levels within normal limits).
Paclitaxel [Taxol; formulated in a mixture of CrEL and dehydrated ethanol
USP (1:1, v/v) provided by Bristol-Myers Squibb] was diluted into 500 ml of
isotonic sodium chloride before dosing. The drug was administered every three
weeks as a 3-h i.v. infusion at consecutive (decreasing) levels of 225, 175, and
135 mg/m2. Premedication consisted of dexamethasone (10 mg i.v.), clemas-
tine (2 mg i.v.), and ranitidine (50 mg i.v.), all given 30 min before start of the
drug administration. During administration, no other comedication was given
that might interfere with paclitaxel disposition. The clinical protocol was
approved by the Rotterdam Cancer Institute Review Board, and the patients
gave written consent before entering the study.
Blood samples (;6 ml) were collected in Vacutainer glass tubes containing
143 USP units of lithium heparin as anticoagulant at 1, 2, and 3 h during
infusion, and at 5, 15, and 30 min, and 1, 2, 4, 6, 8, 12, and 21 h after end of
the infusion. After agitation, 2-ml aliquots of whole blood were snap-frozen at
220°C at the patient site, and the remaining sample was centrifuged for 5 min
at 4000g. Plasma was transferred into a polystyrene container and snap-frozen
at 220°C. All samples were stored at 280°C until analysis. The concentration
of paclitaxel in total plasma (Cp) and whole blood (Cb) was determined by
isocratic reversed-phase HPLC with UV detection at l 5 230 nm, as described
(Sparreboom et al., 1998a). The unbound paclitaxel concentration (Cu) was
estimated from the product of Cp and fu in each individual pharmacokinetic
sample. The analytical procedure for CrEL in plasma samples was based on a
colorimetric dye-binding microassay using Coomassie Brilliant Blue G-250
(Sparreboom et al., 1998b), with modifications as described (Brouwer et al.,
1998).
Paclitaxel concentration-time profiles of Cu, Cp, and Cb were analyzed
using the Siphar software package (version 4.0; SIMED, Cre´teil, France), by
determination of slopes and intercepts of the plotted curves with multiexpo-
nential functions. The program determined initial parameter estimates, and
these were improved using an iterative numerical algorithm based on Powell’s
method. Model discrimination was assessed by a variety of considerations
including visual inspection of the predicted curves, dispersion of residuals,
minimization of the sum of weighted squares residuals, and the Akaike
information criterion. Final values of the iterated parameters of the best-fit
equation were used to calculate pharmacokinetic parameters, including the
terminal disposition half-life (t1/2, z), area under the concentration-time curve
(AUC) from zero to infinity, and clearance (CL, defined as dose divided by
AUC). The peak concentration (Cmax) was put on par with the observed drug
level at the end of infusion. Noncompartmental analysis of CrEL plasma
concentration data was performed as described previously (Sparreboom et al.,
1998d). All statistical tests were calculated using the Number Cruncher Sta-
tistical System package (version 5.X; Dr. J. Hintze, Kaysville, UT).
FIG. 1. Chemical structures of paclitaxel (A) and the major component of CrEL,
polyoxyethyleneglycerol triricinoleate (B).
TABLE 1
Characteristics of patients undergoing blood and plasma sampling during and
after paclitaxel infusion
Characteristic Patient 1 Patient 2 Patient 3
Baseline screening
Age (years) 64 62 51
Gender Female Male Female
Height (cm) 164 167 168
Weight (kg) 69.7 64.4 61.4
BSA (m2) 1.76 1.72 1.70
WHO PS 1 1 0
Primary tumor NSCLC Bladder ACUP
Pretherapy clinical chemistry values
Serum creatinine (mM) 82 93 69
Total bilirubin (mM) 8.0 8.0 3.0
ASAT (units/l) 10 18 26
ALAT (units/l) 16 12 31
Total protein (mg/ml) 78 74 72
Serum albumin (mg/ml) 43 36 45
Worst observed toxicity (according to NCI-CTC grading)
135 mg/m2
175 mg/m2
225 mg/m2 Nausea 2 WBC 3/ANC 2 Nausea 1
BSA, body surface area; WHO PS, World Health Organization performance status; NSCLC,
non-small cell lung cancer; ACUP, adenocarcinoma of unknown primary origin; ASAT, aspar-
tate aminotransferase; ALAT, alanine aminotransferase; NCI-CTC, National Cancer Institute
common toxicity criteria; WBC, white blood cell count (leukocytopenia); ANC, absolute neu-
trophil count (neutropenia).
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Results and Discussion
In Vitro Binding Experiments. We initially investigated ultrafil-
tration, as measurement of paclitaxel in the ultrafiltrate would provide
a direct measure of Cu (Bowers et al., 1984). This technique, using a
standard micro system (Amicon Centrifree, Danvers, MA), however,
gave nonreproducible results and posed serious hurdles owing to a
problem of sensitivity with currently available analytical methods for
the determination of paclitaxel (reviewed in Sparreboom et al.,
1998a). As a next step, we evaluated the possibility of using equilib-
rium dialysis to determine the effects of CrEL on paclitaxel fu in
human plasma. The major prerequisite in determining paclitaxel Cu is
that the condition of the in vitro measurement should simulate those
existing in vivo when the blood sample was taken. Hence, all mea-
surements were carried out with undiluted plasma and at 37°C to give
meaningful results. It was confirmed in all equilibrium dialysis ex-
periments that the total drug recovery from all the fractions was equal
to the amount of [G-3H]paclitaxel added to the plasma samples (P .
.29 versus hypothesized mean of initial value).
In the absence of CrEL, paclitaxel was found to bind extensively to
human plasma, probably due to nonspecific hydrophobic binding to
both serum albumin and a1-acid glycoprotein (Kumar et al., 1993),
with a mean (6 S.D.) fu of 0.13 6 0.016 (n 5 14). This value is
within the same range as described previously in human plasma
samples as determined by both equilibrium dialysis and ultrafiltration
techniques (Longnecker et al., 1987; Wiernik et al., 1987; Jamis-Dow
et al., 1993; Van Tellingen et al., 1999). Experiments demonstrated
that the radioactivity seen in the protein-free fraction was not derived
from any radioactive material that might have been associated with
the polypropylene tube wall or the membrane. Very small amounts of
3H-labeled water were formed, however, during the course of the 24-h
incubation experiments. This was determined in selected buffer sam-
ples as the difference before and after drying (at 37°C) following
equilibrium dialysis in the absence or presence of 5.0 ml/ml (pacli-
taxel, 1.2 mM). It accounted for #4.7% of total radioactivity and was
independent of the CrEL concentration applied. The buffer solutions
collected after dialysis of paclitaxel (12 mM) were also analyzed by a
specific HPLC method (Sparreboom et al., 1998a) to exclude an
artifact due to alteration of the fraction of total radioactivity associated
with unchanged compound (not shown).
As fu measurements were to be made on patient samples that
contained variable amounts of paclitaxel, fu was also determined in
blank plasma samples over the entire anticipated concentration range
(0.03, 0.12, 0.30, 0.60, and 1.2 mM). Paclitaxel concentration had no
influence on fu as determined by unweighted ANOVA (P 5 .19; n 5
36), with an overall coefficient of variation of 4.2%, indicative of a
lack in saturation of paclitaxel binding to human plasma. In the
presence of CrEL, however, a clear and statistically significant de-
crease in fu of paclitaxel (1.2 mM) was observed, which was distinctly
concentration-dependent within the clinical range (P , .00001, one-
way ANOVA). At the highest CrEL concentration tested, i.e., 5 ml/ml,
a decrease of (about) 60% was noted in fu as compared to fu in the
absence of CrEL (Fig. 2).
During the establishment of the method, duplicate or triplicate
plasma samples with differing paclitaxel fu values depending on the
spiked CrEL concentrations were subject to repeated analysis on 6
consecutive days, to assess reproducibility. The mean relative devia-
tion of these samples was 9.2% (n 5 82), assuring high discriminatory
power in the detection of changes in paclitaxel fu in the presence of
CrEL. With the final method, the within-run and between-run vari-
ability, expressed as the percentage relative standard deviation calcu-
lated by one-way ANOVA (Shah et al., 1991), were always less than
9.2% at the six CrEL concentrations analyzed (Table 2). These values
are comparable with that obtained for a variety of other compounds
using equilibrium dialysis or ultrafiltration techniques (Verbeeck and
Cardinal, 1985; Legg and Rowland, 1987), and were considered to be
FIG. 2. Extent of binding of paclitaxel to human plasma, expressed as the
unbound fraction (fu), as a function of the spiked CrEL concentration.
Data are presented as mean values 6 S.D. of fourteen independent observations.
FIG. 3. Fraction unbound paclitaxel (fu) versus time curves in three patients
receiving three 3-weekly courses of the drug formulated at 6 mg/ml in a mixture
of CrEL-dehydrated ethanol USP (1:1, v/v) at dose levels of 135 mg/m2 (), 175
mg/m2 (E) and 225 mg/m2 (F).
Data are presented as mean values (symbol) 6 S.D. (error bar).
TABLE 2
Within-run and between-run variability for analysis of paclitaxel fu in spiked
human plasma samples in the absence and presence of CrEL
CrEL GM WRP BRP n
ml/ml % %
0 0.129 4.1 3.0 14
0.1 0.115 5.4 3.3 14
0.25 0.117 7.2 2.5 14
1.00 0.0977 4.5 2.9 13
2.50 0.0750 9.2 0.77 14
5.00 0.0545 5.8 1.4 13
GM, grand mean of paclitaxel fu; WRP, within-run precision; BRP, between-run precision;
n, total number of observations.
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acceptable for analysis of patient samples in support of pharmacoki-
netic studies.
Patient Studies. The developed method was applied to plasma
samples of three patients treated with paclitaxel at three different dose
levels. Similar to our in vitro experiments, a distinct CrEL concen-
tration and time dependence was noted for paclitaxel fu (Fig. 3).
Logarithmic concentration-time profiles of paclitaxel Cu, and total
paclitaxel in plasma and whole blood are shown in Fig. 4 (upper
panel). Plasma AUC values of total paclitaxel increased dispropor-
tional with dose from 10.2 6 1.34 to 15.5 6 1.38 and 31.8 6 5.40
mM z h at dose levels of 135, 175, and 225 mg/m2, respectively, which
is in excellent agreement with earlier studies (Gianni et al., 1995;
Bhalla et al., 1999). Disproportionality was less pronounced with data
based on fu and whole blood, as indicated by the respective clearance
values as a function of the dose administered (Fig. 4; lower panel).
The overall mean values for paclitaxel fu and whole blood clearance
[255 6 33.1 l/h/m2 (coefficient of variation: 13.0%) and 16.0 6 3.22
l/h/m2 (coefficient of variation: 20.1%), respectively] were relatively
consistent in the three patients, suggesting minor interindividual vari-
ability. In addition, preliminary analysis showed that a linear two-
compartment model could adequately describe the Cu versus time
curves based on the Akaike information criterion (r2 5 0.99 6 0.01;
P , .0001), whereas linear models for total paclitaxel plasma data
were significantly biased (not shown). The terminal disposition half-
life of paclitaxel was similar between dose levels and analyzed ma-
trices, with mean values of 6.54 6 1.43 h (Cu), 7.10 6 1.01 h (Cp),
and 6.91 6 0.97 h (Cb). In all, these findings, although preliminary,
corroborate our hypothesis that the AUC of unbound paclitaxel should
FIG. 4. Concentration-time curves of paclitaxel and paclitaxal clearance.
Upper panel, concentration-time curves of paclitaxel displayed as unbound concentration (A), total plasma concentration (B), and whole blood concentration (C) in three
patients receiving three 3-weekly courses of the drug formulated at 6 mg/ml in a mixture of CrEL-dehydrated ethanol USP (1:1, v/v) at dose levels of 135 mg/m2 (), 175
mg/m2 (E) and 225 mg/m2 (F). Lower panel, paclitaxel clearance of unbound drug (A), total plasma concentration (B), and whole blood concentration (C) as a function
of the total dose administered. Data are presented as mean values (symbol) 6 S.D. (error bar).
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be a linear function of the dose administered, in spite of the nonlinear
disposition profile when only total paclitaxel plasma levels are con-
sidered (Sparreboom et al., 1999a). Mean plasma concentration-time
profiles of CrEL following paclitaxel administration are shown in Fig.
5. As expected, the apparent plasma clearance of CrEL was dose-
independent in each patient and averaged 331 6 48.8 l/h/m2, with
Cmax levels progressively increasing from 2.56 6 0.48 to 3.60 6 0.67
and 4.14 6 0.55 ml/ml at the three consecutive dose levels, which is
within the range described earlier (Sparreboom et al., 1998d).
In conclusion, we have demonstrated, by using a reliable and
reproducible equilibrium dialysis method, that paclitaxel fu in human
samples is significantly influenced by the presence of CrEL in vitro
and in vivo. This effect of CrEL has been shown to be concentration-
dependent, leading to changes in the pharmacokinetic behavior of
paclitaxel. It is proposed that paclitaxel Cu should be monitored to
further define relationships between drug exposure measures and
pharmacodynamic outcome of treatment. Future studies will focus on
this aspect in addition to the mechanism for the increased paclitaxel
binding in the presence of CrEL.
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